Symbols / OPK
OPK Chart
About
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 968.42M |
| Enterprise Value | 920.04M | Income | -180.40M | Sales | 642.07M |
| Book/sh | 1.70 | Cash/sh | 0.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2997 | IPO | — |
| P/E | — | Forward P/E | -3.94 | PEG | — |
| P/S | 1.51 | P/B | 0.72 | P/C | — |
| EV/EBITDA | -7.94 | EV/Sales | 1.43 | Quick Ratio | 3.05 |
| Current Ratio | 3.70 | Debt/Eq | 30.29 | LT Debt/Eq | — |
| EPS (ttm) | -0.24 | EPS next Y | -0.31 | EPS Growth | -12.60% |
| Revenue Growth | -12.60% | Earnings | 2026-02-26 | ROA | -6.15% |
| ROE | -13.32% | ROIC | — | Gross Margin | 18.93% |
| Oper. Margin | -35.29% | Profit Margin | -28.10% | Shs Outstand | 767.70M |
| Shs Float | 347.99M | Short Float | 7.02% | Short Ratio | 8.45 |
| Short Interest | — | 52W High | 2.04 | 52W Low | 1.11 |
| Beta | 1.49 | Avg Volume | 3.34M | Volume | 1.28M |
| Target Price | $3.56 | Recom | Buy | Prev Close | $1.23 |
| Price | $1.22 | Change | -0.81% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.56
Mean price target
2. Current target
$1.22
Latest analyst target
3. DCF / Fair value
$-3.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.22
Low
$1.60
High
$8.50
Mean
$3.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-20 | init | JP Morgan | — → Neutral | — |
| 2025-10-31 | down | Jefferies | Buy → Hold | $2 |
| 2025-10-30 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-05-01 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-04-25 | init | JP Morgan | — → Neutral | — |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-28 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-20 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-17 | reit | Piper Sandler | Overweight → Overweight | $3 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-07-18 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
News
RSS: Latest OPK news- Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Yahoo Finance Wed, 18 Feb 2026 01
- Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Insider Monkey Wed, 18 Feb 2026 01
- OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026 - Quiver Quantitative hu, 12 Feb 2026 13
- Daily oral PTH tablet targets relief from hypoparathyroidism injections - Stock Titan Wed, 04 Feb 2026 08
- Opko Health CEO Phillip Frost buys $737,747 in OPK stock - Investing.com ue, 18 Nov 2025 08
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire hu, 12 Feb 2026 13
- OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap - simplywall.st hu, 08 Jan 2026 08
- OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha ue, 27 Jan 2026 08
- OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results - OPKO Health, Inc. Wed, 30 Apr 2025 07
- Opko Health, Inc. (OPK) Stock Analysis: Exploring a Potential 178% Upside with Strong Buy Ratings - DirectorsTalk Interviews ue, 12 Aug 2025 07
- The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade - Yahoo Finance hu, 20 Nov 2025 08
- Insider Purchase: CEO & Chairman of $OPK Buys 155,496 Shares | OPK Stock News - Quiver Quantitative Wed, 19 Nov 2025 08
- OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up - simplywall.st Fri, 19 Sep 2025 07
- OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands - Yahoo Finance Fri, 01 Aug 2025 07
- OPKO HEALTH Earnings Results: $OPK Reports Quarterly Earnings - Quiver Quantitative Wed, 29 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 580000 | 768807 | — | Purchase at price 1.30 - 1.34 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-11-21 00:00:00 | I |
| 1 | 580000 | 771328 | — | Purchase at price 1.32 - 1.35 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-20 00:00:00 | I |
| 2 | 580000 | 759115 | — | Purchase at price 1.28 - 1.32 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-11-19 00:00:00 | I |
| 3 | 46700 | 58842 | — | Stock Award(Grant) at price 1.26 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-18 00:00:00 | I |
| 4 | 533300 | 678906 | — | Purchase at price 1.24 - 1.29 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-18 00:00:00 | I |
| 5 | 150000 | 213435 | — | Purchase at price 1.42 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-31 00:00:00 | I |
| 6 | 440000 | — | — | Stock Gift at price 0.00 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-18 00:00:00 | I |
| 7 | 675000 | 891000 | — | Purchase at price 1.32 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-08-08 00:00:00 | I |
| 8 | 125000 | 184650 | — | Purchase at price 1.48 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-08 00:00:00 | I |
| 9 | 100000 | 164850 | — | Purchase at price 1.65 per share. | FROST PHILLIP MD ET AL | Chief Executive Officer | — | 2025-04-01 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 20.02M | 53.55K | 3.32M | 9.20M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.16 | 0.27 |
| NormalizedEBITDA | 39.95M | -65.77M | -291.33M | 49.51M |
| TotalUnusualItems | 95.33M | 255.00K | 20.52M | 34.06M |
| TotalUnusualItemsExcludingGoodwill | 95.33M | 255.00K | 20.52M | 34.06M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -53.22M | -188.86M | -328.40M | -30.14M |
| ReconciledDepreciation | 98.18M | 105.30M | 108.66M | 78.72M |
| ReconciledCostOfRevenue | 479.09M | 526.10M | 695.11M | 1.16B |
| EBITDA | 135.28M | -65.52M | -270.81M | 83.57M |
| EBIT | 37.10M | -170.81M | -379.46M | 4.86M |
| NetInterestIncome | -39.04M | -9.52M | -10.07M | -18.85M |
| InterestExpense | 47.47M | 13.51M | 12.06M | 18.88M |
| InterestIncome | 8.43M | 3.98M | 1.98M | 28.00K |
| NormalizedIncome | -128.54M | -189.06M | -345.60M | -55.00M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -53.22M | -188.86M | -328.40M | -30.14M |
| TotalExpenses | 986.70M | 1.02B | 1.25B | 1.79B |
| TotalOperatingIncomeAsReported | -152.06M | -157.02M | -226.25M | 18.75M |
| DilutedAverageShares | 694.02M | 751.72M | 719.06M | 648.08M |
| BasicAverageShares | 694.02M | 751.72M | 719.06M | 648.08M |
| DilutedEPS | -0.08 | -0.25 | -0.46 | -0.05 |
| BasicEPS | -0.08 | -0.25 | -0.46 | -0.05 |
| DilutedNIAvailtoComStockholders | -53.22M | -188.86M | -328.40M | -30.14M |
| NetIncomeCommonStockholders | -53.22M | -188.86M | -328.40M | -30.14M |
| NetIncome | -53.22M | -188.86M | -328.40M | -30.14M |
| NetIncomeIncludingNoncontrollingInterests | -53.22M | -188.86M | -328.40M | -30.14M |
| NetIncomeContinuousOperations | -53.22M | -188.86M | -328.40M | -30.14M |
| EarningsFromEquityInterestNetOfTax | -18.00K | -107.00K | -383.00K | -629.00K |
| TaxProvision | 42.84M | 4.44M | -63.50M | 15.49M |
| PretaxIncome | -10.36M | -184.32M | -391.52M | -14.03M |
| OtherIncomeExpense | 302.24M | -16.74M | -135.32M | 19.29M |
| OtherNonOperatingIncomeExpenses | 206.90M | -16.99M | -155.84M | -14.77M |
| SpecialIncomeCharges | 121.49M | 1.04M | 19.87M | 33.21M |
| GainOnSaleOfPPE | 121.49M | 0.00 | 18.56M | 31.51M |
| WriteOff | 0.00 | |||
| RestructuringAndMergernAcquisition | 0.00 | -1.04M | -1.31M | -1.70M |
| GainOnSaleOfSecurity | -26.16M | -781.00K | 649.00K | 846.00K |
| NetNonOperatingInterestIncomeExpense | -39.04M | -9.52M | -10.07M | -18.85M |
| InterestExpenseNonOperating | 47.47M | 13.51M | 12.06M | 18.88M |
| InterestIncomeNonOperating | 8.43M | 3.98M | 1.98M | 28.00K |
| OperatingIncome | -273.56M | -158.06M | -246.12M | -14.46M |
| OperatingExpense | 492.07M | 476.18M | 534.34M | 595.99M |
| DepreciationAmortizationDepletionIncomeStatement | 82.63M | 86.03M | 87.78M | 50.28M |
| DepreciationAndAmortizationInIncomeStatement | 82.63M | 86.03M | 87.78M | 50.28M |
| Amortization | 82.63M | 86.03M | 87.78M | 50.28M |
| AmortizationOfIntangiblesIncomeStatement | 82.63M | 86.03M | 87.78M | 50.28M |
| ResearchAndDevelopment | 105.21M | 89.59M | 73.89M | 76.85M |
| SellingGeneralAndAdministration | 304.22M | 300.56M | 372.67M | 468.86M |
| GrossProfit | 218.51M | 318.13M | 288.22M | 581.52M |
| CostOfRevenue | 494.63M | 545.37M | 715.98M | 1.19B |
| TotalRevenue | 713.14M | 863.50M | 1.00B | 1.77B |
| OperatingRevenue | 713.14M | 863.50M | 1.00B | 1.77B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 29.80M | 8.66M | 8.66M | 8.66M |
| OrdinarySharesNumber | 671.55M | 773.28M | 772.65M | 681.43M |
| ShareIssued | 701.35M | 781.94M | 781.31M | 690.08M |
| NetDebt | 5.27M | 153.45M | 102.87M | 70.14M |
| TotalDebt | 504.44M | 326.56M | 305.55M | 254.75M |
| TangibleBookValue | 24.58M | -144.32M | -52.72M | 252.64M |
| InvestedCapital | 1.80B | 1.64B | 1.82B | 1.89B |
| WorkingCapital | 468.99M | 109.42M | 181.04M | 493.01M |
| NetTangibleAssets | 24.58M | -144.32M | -52.72M | 252.64M |
| CapitalLeaseObligations | 67.24M | 77.24M | 49.49M | 49.90M |
| CommonStockEquity | 1.37B | 1.39B | 1.56B | 1.69B |
| TotalCapitalization | 1.79B | 1.61B | 1.78B | 1.88B |
| TotalEquityGrossMinorityInterest | 1.37B | 1.39B | 1.56B | 1.69B |
| StockholdersEquity | 1.37B | 1.39B | 1.56B | 1.69B |
| GainsLossesNotAffectingRetainedEarnings | -56.13M | -38.03M | -43.32M | -30.50M |
| OtherEquityAdjustments | -56.13M | -38.03M | -43.32M | -30.50M |
| TreasuryStock | 1.79M | 1.79M | 1.79M | 1.79M |
| RetainedEarnings | -2.07B | -2.01B | -1.82B | -1.51B |
| AdditionalPaidInCapital | 3.48B | 3.43B | 3.42B | 3.22B |
| CapitalStock | 7.01M | 7.82M | 7.81M | 6.90M |
| CommonStock | 7.01M | 7.82M | 7.81M | 6.90M |
| TotalLiabilitiesNetMinorityInterest | 834.76M | 622.48M | 605.61M | 714.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 641.67M | 422.43M | 392.13M | 384.58M |
| OtherNonCurrentLiabilities | 11.50M | 12.20M | 11.05M | 9.71M |
| EmployeeBenefits | 14.27M | 0.00 | ||
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 14.27M | 0.00 | ||
| NonCurrentDeferredLiabilities | 140.81M | 126.78M | 126.56M | 148.69M |
| NonCurrentDeferredRevenue | 6.00K | 7.00K | 138.00K | 208.00K |
| NonCurrentDeferredTaxesLiabilities | 140.80M | 126.77M | 126.43M | 148.49M |
| LongTermDebtAndCapitalLeaseObligation | 475.10M | 283.45M | 254.52M | 226.18M |
| LongTermCapitalLeaseObligation | 52.91M | 61.41M | 35.05M | 36.02M |
| LongTermDebt | 422.18M | 222.03M | 219.47M | 190.16M |
| CurrentLiabilities | 193.10M | 200.05M | 213.48M | 330.01M |
| OtherCurrentLiabilities | 28.16M | |||
| CurrentDeferredLiabilities | 0.00 | 0.00 | 258.00K | |
| CurrentDeferredRevenue | 0.00 | 0.00 | 258.00K | |
| CurrentDebtAndCapitalLeaseObligation | 29.35M | 43.12M | 51.03M | 28.57M |
| CurrentCapitalLeaseObligation | 14.33M | 15.82M | 14.44M | 13.88M |
| CurrentDebt | 15.02M | 27.29M | 36.59M | 14.69M |
| OtherCurrentBorrowings | 15.02M | 27.29M | 36.59M | 14.69M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 34.17M | 28.95M | 33.77M | 45.94M |
| CurrentProvisions | 6.92M | 9.42M | 6.48M | |
| PayablesAndAccruedExpenses | 122.66M | 118.56M | 122.21M | 227.08M |
| CurrentAccruedExpenses | 53.32M | 47.50M | 49.87M | 145.04M |
| InterestPayable | 8.31M | |||
| Payables | 69.35M | 71.06M | 72.34M | 82.04M |
| TotalTaxPayable | 22.27M | 1.38M | 5.35M | |
| AccountsPayable | 47.07M | 69.68M | 66.99M | 82.04M |
| TotalAssets | 2.20B | 2.01B | 2.17B | 2.40B |
| TotalNonCurrentAssets | 1.54B | 1.70B | 1.77B | 1.58B |
| OtherNonCurrentAssets | 18.54M | 9.08M | 8.68M | 9.53M |
| FinancialAssets | 3.00K | 2.00K | 28.00K | 16.00K |
| InvestmentsAndAdvances | 54.58M | 16.08M | 28.05M | 10.71M |
| InvestmentinFinancialAssets | 53.79M | 5.50M | 6.03M | 9.63M |
| AvailableForSaleSecurities | 53.79M | 5.50M | 6.03M | 9.63M |
| LongTermEquityInvestment | 787.00K | 10.58M | 22.02M | 1.08M |
| GoodwillAndOtherIntangibleAssets | 1.34B | 1.53B | 1.61B | 1.43B |
| OtherIntangibleAssets | 811.61M | 935.28M | 1.02B | 911.88M |
| Goodwill | 529.25M | 598.26M | 595.85M | 520.60M |
| NetPPE | 124.14M | 143.52M | 121.60M | 123.95M |
| AccumulatedDepreciation | -138.70M | -157.13M | -142.41M | -133.33M |
| GrossPPE | 262.84M | 300.64M | 264.01M | 257.28M |
| Leases | 20.94M | 28.06M | 25.52M | 27.48M |
| ConstructionInProgress | 19.23M | 5.25M | 4.79M | 6.11M |
| OtherProperties | 54.00M | 68.09M | 38.73M | 44.23M |
| MachineryFurnitureEquipment | 153.36M | 177.93M | 174.34M | 166.38M |
| BuildingsAndImprovements | 13.06M | 18.89M | 18.31M | 10.66M |
| LandAndImprovements | 2.24M | 2.42M | 2.32M | 2.42M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 662.09M | 309.48M | 394.52M | 823.01M |
| OtherCurrentAssets | 10.71M | 7.67M | 6.25M | 6.20M |
| AssetsHeldForSaleCurrent | 0.00 | 314.99M | ||
| PrepaidAssets | 10.60M | 10.03M | 12.41M | 15.02M |
| Inventory | 56.80M | 65.70M | 74.06M | 86.50M |
| InventoriesAdjustmentsAllowances | -2.77M | -6.46M | -3.57M | -4.78M |
| FinishedGoods | 32.31M | 35.58M | 37.14M | 44.11M |
| WorkInProcess | 2.35M | 1.73M | 2.45M | 1.61M |
| RawMaterials | 24.91M | 34.84M | 38.05M | 45.56M |
| Receivables | 152.05M | 130.20M | 148.61M | 265.59M |
| OtherReceivables | 25.77M | 2.61M | 13.11M | 353.00K |
| TaxesReceivable | 8.27M | 4.21M | 8.19M | 5.60M |
| AccountsReceivable | 118.02M | 123.38M | 127.31M | 259.64M |
| AllowanceForDoubtfulAccountsReceivable | -1.27M | -2.00M | -4.16M | -1.84M |
| GrossAccountsReceivable | 119.28M | 125.38M | 131.47M | 261.48M |
| CashCashEquivalentsAndShortTermInvestments | 431.94M | 95.88M | 153.19M | 134.71M |
| CashAndCashEquivalents | 431.94M | 95.88M | 153.19M | 134.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -208.50M | -44.47M | -119.77M | 6.18M |
| RepurchaseOfCapitalStock | -90.22M | 0.00 | 0.00 | |
| RepaymentOfDebt | -651.45M | -682.71M | -1.04B | -1.70B |
| IssuanceOfDebt | 939.43M | 671.68M | 1.06B | 1.68B |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -25.01M | -16.27M | -24.58M | -32.16M |
| InterestPaidSupplementalData | 20.88M | 8.13M | 7.42M | 8.52M |
| IncomeTaxPaidSupplementalData | 10.01M | 3.71M | 8.04M | 5.97M |
| EndCashPosition | 445.62M | 95.88M | 153.19M | 134.71M |
| BeginningCashPosition | 95.88M | 153.19M | 134.71M | 72.21M |
| EffectOfExchangeRateChanges | -3.16M | 388.00K | -339.00K | -1.44M |
| ChangesInCash | 352.89M | -57.70M | 18.82M | 63.94M |
| FinancingCashFlow | 184.17M | -11.30M | 22.97M | -10.35M |
| CashFlowFromContinuingFinancingActivities | 184.17M | -11.30M | 22.97M | -10.35M |
| NetOtherFinancingCharges | -13.38M | -188.00K | ||
| ProceedsFromStockOptionExercised | -208.00K | -272.00K | -774.00K | 1.08M |
| NetCommonStockIssuance | -90.22M | 0.00 | 0.00 | 0.00 |
| CommonStockPayments | -90.22M | 0.00 | 0.00 | |
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 287.98M | -11.03M | 23.75M | -11.24M |
| NetShortTermDebtIssuance | -11.24M | |||
| ShortTermDebtPayments | -1.70B | |||
| ShortTermDebtIssuance | 1.68B | |||
| NetLongTermDebtIssuance | 287.98M | -11.03M | 23.75M | -11.24M |
| LongTermDebtPayments | -651.45M | -682.71M | -1.04B | -1.70B |
| LongTermDebtIssuance | 939.43M | 671.68M | 1.06B | 1.68B |
| InvestingCashFlow | 352.21M | -18.20M | 91.04M | 35.95M |
| CashFlowFromContinuingInvestingActivities | 352.21M | -18.20M | 91.04M | 35.95M |
| NetInvestmentPurchaseAndSale | 166.60M | 364.00K | 115.42M | 8.08M |
| SaleOfInvestment | 166.60M | 364.00K | 115.42M | 8.08M |
| NetBusinessPurchaseAndSale | 210.38M | -5.00M | -1.76M | -6.00M |
| SaleOfBusiness | 210.38M | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | -5.00M | -1.76M | -6.00M |
| NetPPEPurchaseAndSale | 242.00K | 2.71M | 1.95M | 66.03M |
| SaleOfPPE | 242.00K | 2.71M | 1.95M | 66.03M |
| CapitalExpenditureReported | -25.01M | -16.27M | -24.58M | -32.16M |
| OperatingCashFlow | -183.49M | -28.20M | -95.19M | 38.34M |
| CashFlowFromContinuingOperatingActivities | -183.49M | -28.20M | -95.19M | 38.34M |
| ChangeInWorkingCapital | 32.17M | 21.80M | 42.65M | -20.48M |
| ChangeInOtherWorkingCapital | 3.90M | -1.04M | 2.37M | -13.57M |
| ChangeInOtherCurrentAssets | -3.74M | 6.88M | -1.48M | 1.74M |
| ChangeInPayablesAndAccruedExpense | 28.02M | -2.65M | -100.50M | -44.57M |
| ChangeInAccruedExpense | 48.68M | -5.48M | -91.11M | -33.72M |
| ChangeInPayable | -20.66M | 2.83M | -9.39M | -10.85M |
| ChangeInAccountPayable | -20.66M | 2.83M | -9.39M | -10.85M |
| ChangeInInventory | 4.22M | 15.20M | 13.66M | 30.68M |
| ChangeInReceivables | -220.00K | 3.41M | 128.60M | 5.23M |
| ChangesInAccountReceivables | -220.00K | 3.41M | 128.60M | 5.23M |
| OtherNonCashItems | 12.89M | 2.94M | 2.60M | 15.78M |
| StockBasedCompensation | 11.05M | 11.41M | 18.51M | 13.63M |
| UnrealizedGainLossOnInvestmentSecurities | -114.43M | 17.65M | 153.84M | 3.97M |
| AssetImpairmentCharge | 0.00 | |||
| DeferredTax | 14.74M | 146.00K | -74.41M | 10.16M |
| DeferredIncomeTax | 14.74M | 146.00K | -74.41M | 10.16M |
| DepreciationAmortizationDepletion | 98.18M | 105.30M | 108.66M | 78.72M |
| DepreciationAndAmortization | 98.18M | 105.30M | 108.66M | 78.72M |
| OperatingGainsLosses | -184.87M | 1.43M | -18.63M | -33.29M |
| EarningsLossesFromEquityInvestments | 18.00K | 107.00K | 383.00K | 629.00K |
| NetForeignCurrencyExchangeGainLoss | 2.35M | |||
| GainLossOnSaleOfPPE | -63.40M | 1.32M | -455.00K | -33.92M |
| GainLossOnSaleOfBusiness | 0.00 | -18.56M | 0.00 | |
| NetIncomeFromContinuingOperations | -53.22M | -188.86M | -328.40M | -30.14M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OPK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|